Skip to main content
Erschienen in: Irish Journal of Medical Science (1971 -) 3/2011

01.09.2011 | Original Article

Therapy with omalizumab for patients with severe allergic asthma improves asthma control and reduces overall healthcare costs

verfasst von: R. W. Costello, D. A. Long, S. Gaine, T. Mc Donnell, J. J. Gilmartin, S. J. Lane

Erschienen in: Irish Journal of Medical Science (1971 -) | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

Background

Patients with asthma who have persistent symptoms despite treatment with inhaled steroids and long-acting beta agonists are considered to have severe asthma. Omalizumab is a monoclonal antibody directed against IgE, which is used as an add-on treatment for patients who have severe persistent allergic asthma.

Aims

The aim of this study was to assess the clinical benefit and healthcare utilisation of patients who responded to omalizumab therapy and to establish an overall cost implication.

Methods

This was an observational retrospective cohort study designed to investigate the effect of omalizumab on exacerbations of asthma before and after 6 months of treatment in Irish patients.

Results

Centres who had treated patients with severe allergic asthma for the 6 months prior and post omalizumab treatment were audited with a standardised assessment tool. Sixty-three (32 male) patients were studied. In the 6 months prior to omalizumab 41 of 63 (66%) had been hospitalised, and this fell to 15 of 63 (24%), p < 0.0001 in the 6 months after treatment was started. Hospital admissions reduced from 2.4 ± 0.41 to 0.8 ± 0.37 and the mean number of bed days occupied was reduced from 16.6 ± 2.94 to 5.3 ± 2.57 days, p < 0.001. The number of oral corticosteroid doses used fell from 3.1 ± 0.27 to 1.2 ± 0.17, p < 0.001. The overall cost saving per omalizumab responder patients for 6 months was €834.

Conclusions

Six months therapy with omalizumab reduced the number of bed days, the number of hospitalisations and the use of oral corticosteroids compared to the 6 months prior to commencement. Despite the cost of the additional therapy there were overall savings in health costs.
Literatur
1.
Zurück zum Zitat Heaney LG, Brightling CE, Menzies-Gow A et al (2010) Refractory asthma in the UK: cross-sectional findings from a UK multicentre registry. Thorax 65(9):787–794PubMedCrossRef Heaney LG, Brightling CE, Menzies-Gow A et al (2010) Refractory asthma in the UK: cross-sectional findings from a UK multicentre registry. Thorax 65(9):787–794PubMedCrossRef
2.
Zurück zum Zitat Moore WC, Bleecker ER, Curran-Everett D et al (2007) Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute’s Severe Asthma Research Program. J Allergy Clin Immunol 119(2):405–413PubMedCrossRef Moore WC, Bleecker ER, Curran-Everett D et al (2007) Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute’s Severe Asthma Research Program. J Allergy Clin Immunol 119(2):405–413PubMedCrossRef
3.
Zurück zum Zitat Lloyd A, Price D, Brown R (2007) The impact of asthma exacerbations on health-related quality of life in moderate to severe asthma patients in the UK. Prim Care Respir J 16(1):22–27PubMedCrossRef Lloyd A, Price D, Brown R (2007) The impact of asthma exacerbations on health-related quality of life in moderate to severe asthma patients in the UK. Prim Care Respir J 16(1):22–27PubMedCrossRef
4.
Zurück zum Zitat Rodrigo GJ, Neffen H, Castro-Rodriguez JA (2011) Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review. Chest 139(1):28–35PubMedCrossRef Rodrigo GJ, Neffen H, Castro-Rodriguez JA (2011) Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review. Chest 139(1):28–35PubMedCrossRef
5.
Zurück zum Zitat Firszt R, Kraft M (2010) Pharmacotherapy of severe asthma. Curr Opin Pharmacol 10(3):266–271PubMedCrossRef Firszt R, Kraft M (2010) Pharmacotherapy of severe asthma. Curr Opin Pharmacol 10(3):266–271PubMedCrossRef
6.
Zurück zum Zitat Brusselle G, Michils A, Louis R et al (2009) “Real-life” effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study. Respir Med 103(11):1633–1642PubMedCrossRef Brusselle G, Michils A, Louis R et al (2009) “Real-life” effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study. Respir Med 103(11):1633–1642PubMedCrossRef
7.
Zurück zum Zitat Busse W, Corren J, Lanier BQ, McAlary M et al (2001) Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 108(2):184–190PubMedCrossRef Busse W, Corren J, Lanier BQ, McAlary M et al (2001) Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 108(2):184–190PubMedCrossRef
8.
Zurück zum Zitat Holgate S, Smith N, Massanari M (2009) Effects of omalizumab on markers of inflammation in patients with allergic asthma. Allergy 64(12):1728–1736PubMedCrossRef Holgate S, Smith N, Massanari M (2009) Effects of omalizumab on markers of inflammation in patients with allergic asthma. Allergy 64(12):1728–1736PubMedCrossRef
9.
Zurück zum Zitat Molimard M, de Blay F, Didier A, Le Gros V (2008) Effectiveness of omalizumab (Xolair) in the first patients treated in real-life practice in France. Respir Med 102(1):71–76PubMedCrossRef Molimard M, de Blay F, Didier A, Le Gros V (2008) Effectiveness of omalizumab (Xolair) in the first patients treated in real-life practice in France. Respir Med 102(1):71–76PubMedCrossRef
10.
Zurück zum Zitat Pinto JM, Mehta N, DiTineo M et al (2010) A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis. Rhinology 48(3):318–324PubMed Pinto JM, Mehta N, DiTineo M et al (2010) A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis. Rhinology 48(3):318–324PubMed
11.
Zurück zum Zitat Plewako H, Arvidsson M, Petruson K et al (2002) The effect of omalizumab on nasal allergic inflammation. J Allergy Clin Immunol 110(1):68–71PubMedCrossRef Plewako H, Arvidsson M, Petruson K et al (2002) The effect of omalizumab on nasal allergic inflammation. J Allergy Clin Immunol 110(1):68–71PubMedCrossRef
12.
Zurück zum Zitat Royce SG, Tang ML (2009) The effects of current therapies on airway remodeling in asthma and new possibilities for treatment and prevention. Curr Mol Pharmacol 2:169–181PubMedCrossRef Royce SG, Tang ML (2009) The effects of current therapies on airway remodeling in asthma and new possibilities for treatment and prevention. Curr Mol Pharmacol 2:169–181PubMedCrossRef
13.
Zurück zum Zitat Schleich F, Manise M, Louis R (2009) Omralizumab (Xolair) in severe persistent allergic asthma. Rev Med Liege 64(5-6):313–317PubMed Schleich F, Manise M, Louis R (2009) Omralizumab (Xolair) in severe persistent allergic asthma. Rev Med Liege 64(5-6):313–317PubMed
14.
Zurück zum Zitat Djukanovic R, Wilson SJ, Kraft M et al (2004) Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med 170(6):583–593PubMedCrossRef Djukanovic R, Wilson SJ, Kraft M et al (2004) Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med 170(6):583–593PubMedCrossRef
15.
Zurück zum Zitat Fahy JV, Fleming HE, Wong HH et al (1997) The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 155(6):1828–1834PubMed Fahy JV, Fleming HE, Wong HH et al (1997) The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 155(6):1828–1834PubMed
16.
Zurück zum Zitat Bradding P, Green RH (2010) Subclinical phenotypes of asthma. Curr Opin Allergy Clin Immunol 10(1):54–59PubMedCrossRef Bradding P, Green RH (2010) Subclinical phenotypes of asthma. Curr Opin Allergy Clin Immunol 10(1):54–59PubMedCrossRef
17.
Zurück zum Zitat van den Berge M, Pauw RG, de Monchy JG et al (2011) Beneficial effects of treatment with anti-IgE antibodies (Omalizumab) in a patient with severe asthma and negative skin-prick test results. Chest 139(1):190–193PubMedCrossRef van den Berge M, Pauw RG, de Monchy JG et al (2011) Beneficial effects of treatment with anti-IgE antibodies (Omalizumab) in a patient with severe asthma and negative skin-prick test results. Chest 139(1):190–193PubMedCrossRef
Metadaten
Titel
Therapy with omalizumab for patients with severe allergic asthma improves asthma control and reduces overall healthcare costs
verfasst von
R. W. Costello
D. A. Long
S. Gaine
T. Mc Donnell
J. J. Gilmartin
S. J. Lane
Publikationsdatum
01.09.2011
Verlag
Springer-Verlag
Erschienen in
Irish Journal of Medical Science (1971 -) / Ausgabe 3/2011
Print ISSN: 0021-1265
Elektronische ISSN: 1863-4362
DOI
https://doi.org/10.1007/s11845-011-0716-2

Weitere Artikel der Ausgabe 3/2011

Irish Journal of Medical Science (1971 -) 3/2011 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.